Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02326298 · ClinicalTrials.gov registry record · Phase 3
An Efficacy and Safety Study of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO)
A Phase 3 study of Psoriasis and Plaque Psoriasis, sponsored by UCB Biopharma S.P.R.L..
- Completed
- Registry status
- Phase 3
- Development phase
- 234
- Enrollment target
- 20
- Study locations
NCT02326298 is a Phase 3 study of Psoriasis and Plaque Psoriasis that has completed, run by UCB Biopharma S.P.R.L.. The registered enrollment target is 234 participants, below the 487-participant average among 125 other Psoriasis trials with a reported enrollment target (52% lower). The trial reports 20 study locations across 14 states.
The verdict
NCT02326298, a Phase 3 study of Psoriasis and Plaque Psoriasis, has completed, sponsored by UCB Biopharma S.P.R.L..
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 234 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to investigate the efficacy and safety of two dose levels of certolizumab pegol in adults with moderate to severe chronic plaque psoriasis when administered every 2 weeks.
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL Certolizumab Pegol
Study Locations (20)
Other
- Ps0005 553 - Náchod
- Ps0005 550 - Olomouc
- Ps0005 551 - Ostrava-Poruba
- Ps0005 552 - Prague
Ontario
- Ps0005 596 - Ajax
- Ps0005 590 - Hamilton
- Ps0005 593 - Toronto
Quebec
- Ps0005 595 - Drummondville
- Ps0005 594 - Québec
California
- Ps0005 504 - San Diego
Iowa
- Ps0005 502 - West Des Moines
Louisiana
- Ps0005 500 - Baton Rouge
Massachusetts
- Ps0005 506 - Boston
Missouri
- Ps0005 505 - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 234 participants |
| Start Date | 2014-12-16 |
| Est. Completion | 2018-10-24 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02326298
The ClinicalTrials.gov registry entry for NCT02326298 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 234 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 487-participant average among 125 other Psoriasis trials with a reported enrollment target (52% lower). The listed sponsor is UCB Biopharma S.P.R.L., which has 23 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Psoriasis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02326298 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Other, Ontario, Quebec.
Frequently Asked Questions
What is clinical trial NCT02326298 about?
NCT02326298 is a clinical study titled "An Efficacy and Safety Study of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO)". The purpose of this study is to investigate the efficacy and safety of two dose levels of certolizumab pegol in adults with moderate to severe chronic plaque psoriasis when administered every 2 weeks.
What is the current status of trial NCT02326298?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 234 participants. The study started on 2014-12-16. Estimated completion is 2018-10-24.
What conditions does trial NCT02326298 study?
This clinical trial studies the following conditions: Psoriasis, Plaque Psoriasis.
What interventions are being tested in trial NCT02326298?
The interventions under investigation include: Placebo (OTHER), Certolizumab Pegol (BIOLOGICAL).
Who is sponsoring clinical trial NCT02326298?
This trial is sponsored by UCB Biopharma S.P.R.L., which has 23 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02326298 being conducted?
This trial has 20 study locations across California, Iowa, Louisiana, Massachusetts, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977
ACTIVE NOT RECRUITING · Phase 3
-
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
ACTIVE NOT RECRUITING · Phase 3
-
Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis
ACTIVE NOT RECRUITING · Phase 3
-
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.